PTGS2 and colorectal carcinoma: In this scenario, Rimonabant would represent a very promising compound able to counteract CRC through a direct inhibition of Wnt/β-Catenin pathway and COX-2/PGE2 axis and indirectly through the modulation of the angiogenesis according to our previous data12.